NLRP1 and neoplasm: Due to the important role of anti-tumor immunity in controlling development of cutaneous SCCs [3], it is tempting to speculate that SCC cells in vivo might profit from attenuation of anti-tumor immune responses downstream of NLRP1 inflammasome suppression.